Autolus Therapeutics (AUTL) vs Entera Bio (ENTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Entera Bio (ENTX) has outperformed Autolus Therapeutics (AUTL) over the past year, gaining 6.0% versus a gain of 2.8%. Over five years, ENTX leads with a -41.2% price change compared with -70.5% for AUTL. Autolus Therapeutics is the larger company by market cap ($481.8 million vs $462.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | ENTX |
|---|---|---|
| Share price | $1.81 | $2.66 |
| Market cap | $481.75M | $462.40M |
| 1-day change | +2.26% | +6.40% |
| YTD return | -9.05% | +37.11% |
| 1-year return | +2.84% | +5.98% |
| 5-year return | -70.52% | -41.15% |
| EPS (TTM) | $-1.09 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.58 | $4.20 |
| 52-week low | $1.18 | $0.91 |
| Distance from 52-week high | -29.84% | -36.67% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +382.32% | +266.54% |
| Average volume | 2.10M | 1.82M |
| Shares outstanding | 266.16M | 173.83M |
| Employees | 752 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
AUTL vs ENTX FAQ
Which is bigger, Autolus Therapeutics or Entera Bio?
Autolus Therapeutics (AUTL) is larger, with a market capitalization of $481.75M compared with $462.40M for Entera Bio (ENTX).
Which stock has performed better over the past year, AUTL or ENTX?
ENTX returned +5.98% over the past 12 months, compared with +2.84% for AUTL (price return, excluding dividends). Past performance does not predict future results.
Are Autolus Therapeutics and Entera Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.